China has sharply restricted investigator-initiated biotech clinical trials after patient deaths, slowing what had been a surge of controversial studies. The change leaves rare disease families with fewer trial options and creates uncertainty for US investors exposed to China’s biotech sector. It matters because tighter oversight may improve safety but could also delay access and complicate cross-border investment.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
A webinar will feature two experts explaining how ultra-sensitive, multiplexed proteomics can measure the pace of biological aging and assess interventions designed to change it. The discussion matters because reliable proteomic measures could help track aging trajectories and evaluate whether candidate treatments are having an effect.
India has proposed rules that would require regulators to immediately suspend manufacturing licenses when government testing shows a drug fails quality standards. For industry professionals, the move signals tighter enforcement and higher compliance risk for manufacturers, with potential implications for supply continuity and quality assurance.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
A sickle cell gene-editing therapy that had been in development for a decade was abruptly halted three years ago after the first treated patient experienced a serious adverse event. The program now appears to have a chance at revival. For professionals in gene therapy and hematology, the development is notable because it could reopen a once-abandoned editing approach for a disease with limited curative options.
A new podcast episode examines the Democrats’ midterm win and what it could mean for drug pricing policy. It also looks at a fertility procedure being questioned and why women are traveling abroad to fertility clinics. For professional readers, the discussion connects election results to pricing policy and highlights cross-border fertility care as an area of scrutiny.
A new study found that a cholesterol drug used beyond statins reduced heart attack risk by 20%. The results could help doctors decide what to prescribe when statins do not adequately control cholesterol, a challenging clinical question. For professional readers
Tissue engineering is advancing on several fronts, with personalized grafts, bioinks for printing living structures, and off-the-shelf tissue products moving regenerative medicine closer to wider clinical use. The shift matters because it suggests the field is progressing from bespoke laboratory work toward approaches that could be manufactured and distributed more broadly. For professionals, the emphasis on off-the-shelf availability points to the practical challenges of scalability, consistency, and regulatory readiness that will determine clinical adoption.
Regenerative MedicineEthics & SafetyCell Therapy IndustryRead more →
The nonprofit biotech has in-licensed its first gene therapy and plans to expand its pipeline. It evaluates candidates based on unmet medical need, clinical evidence of safety and efficacy, and fit with institutional partners. Its funding model combines seed investment with commercial revenue and non-traditional sources, making the first license a signal that the accelerator’s approach is moving into execution and could support more rare-disease therapies.
Clinical TrialsEthics & SafetyCell Therapy IndustryRead more →
Researchers report that an AI-guided engineering approach produced a broadly protective avian influenza vaccine intended to remain effective across a wide range of current and future H5Nx variants. In preclinical testing, it outperformed vaccines currently held in stockpiles, suggesting a potential path to more durable preparedness against evolving bird flu threats.
Boehringer Ingelheim has entered a cancer drug collaboration with Sino Biopharmaceutical with a potential value exceeding $7.4 billion. The pact covers six preclinical biologic programs, five from Sino Biopharm subsidiary LaNova Medicines and one from Beijing Tide Pharmaceutical. For industry watchers, the deal signals continued appetite for early-stage oncology assets from Chinese biopharma groups and a significant potential boost to Boehringer’s cancer pipeline.
Artiva Biotherapeutics has discontinued development of its allogeneic natural killer cell therapy after two patients died in a clinical trial. The halt highlights the safety and risk-management challenges facing off-the-shelf cell therapies, particularly in autoimmune disease settings. Separately, Bristol Myers Squibb reported encouraging Phase I data for Zola-cel, showing continued momentum in cell therapy development despite such setbacks.
Researchers used genome editing in a preclinical model to reactivate an embryonic globin gene, offering a potential new strategy for treating severe alpha-thalassemia. The result is early-stage but provides proof of concept for a therapeutic approach that could be further developed and validated.